Why Wall Street Analysts Are Growing Increasingly Bullish on Abbott Laboratories
Yahoo Finance ·
Abbott Laboratories, a renowned Dividend King with a 54-year streak of consecutive payout increases, is attracting heightened optimism from Wall Street. Beyond its reliable income appeal, the healthcare giant is demonstrating an impressive ability to accelerate earnings growth, primarily driven by the robust momentum of its Medical Devices division. During the second quarter of 2026, the company reported a 13 percent jump in sales to approximately $12.6 billion alongside an adjusted earnings per share of $1.31. Consequently, management upgraded its full-year adjusted EPS guidance to a range of $5.45 to $5.60, while maintaining comparable sales growth estimates at 6.5 percent to 7.5 percent. This stellar performance is reflected in recent analyst sentiments, with 21 buy ratings and price targets spanning from $121.33 to $143. Notable revisions include TD Cowen raising its target to $135, Citi moving to $125, and Wolfe Research upgrading the stock to outperform with a $130 target.
AI 시장 분석
Abbott Laboratories reported a 13% increase in Q2 2026 revenue to $12.6 billion and an increase in adjusted EPS to $1.31, beating Wall Street expectations. Driven by this, the company raised its full-year adjusted EPS guidance, and multiple Wall Street analysts raised their price targets while maintaining buy ratings. From an investor perspective, it is important to watch whether growth in the medical devices segment can drive sustained profit growth.
상승 영향
- Biotechnology — Abbott's 13% Q2 revenue increase and rising adjusted EPS stimulated investment sentiment across the healthcare sector.
DYAX 전담 분석
Abbott's strong Q2 performance is attributed to a sharp surge in revenue and improved profitability in its core medical devices segment, enhancing its appeal as an earnings-growth value stock beyond its title of 54 consecutive years of dividend growth. A 13% revenue increase and raised annual EPS guidance are factors that directly strengthen stock price upward momentum.
The bullish scenario is that sustained expansion in medical device demand leads to exceeding the upper end of the guidance at $5.60 and reaching the price target of $143, while the bearish scenario is that valuation pressure emerges due to questions about future growth sustainability. Quarterly revenue growth rates and EPS trends in the medical devices segment should be monitored as key indicators.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 33% · Bearish (Short) 67%
317 participants
Related News
- Micron Hovers 22% Below Peak Ahead of Earnings: Dip Buy or Red Flag?
- Lemonade Targets First EBITDA-Positive Quarter as CFO Tim Bixby Transitions to Board
- Warren E. Buffett Becomes Berkshire Hathaway Chairman Emeritus, Howard G. Buffett Elected Chairman
- Drax Secures GBP 1.1 Billion from JPMorgan and Banco Santander for Bluefield Acquisition
- Analysis Behind Frontline Stock Price Plunge Today
- What Caused Strategy's Stock Price to Surge Today?
